What 国药控股广州有限公司 does

国药控股广州有限公司 (Sinopharm Holding Guangzhou Co., Ltd.) is a Guangdong-based subsidiary of Sinopharm Holding Co., Ltd. (listed on Shanghai Stock Exchange 601869 and Hong Kong Stock Exchange 01099), itself controlled by the state-owned Sinopharm Group (国药集团) under SASAC. The company is organized as the group's distribution operations headquarters for South China, headquartered at Liwan District, Guangzhou, and operates under a 'one body, two wings' (一体两翼) strategy combining traditional distribution with retail and innovation businesses.

The company operates six core business lines: (1) traditional pharmaceutical distribution (传统业务) to hospitals, clinics, and pharmacies; (2) medical devices and consumables (器械耗材); (3) retail direct sales (零售直销); (4) retail treatment/clinic services via the SPS+ professional pharmacy chain (零售诊疗); (5) pharmaceutical logistics with cold-chain capability (医药物流); and (6) an innovation business segment covering digital transformation and emerging service models (创新业务). It also operates a proprietary B2B e-commerce platform (511yao.com) for online procurement. Its principal customers are public and non-public hospitals, medical institutions, individual patients through SPS+ pharmacies, and medical device suppliers, with named engagements including Guangzhou Medical University Affiliated Tumor Hospital and BeiGene.

Revenue is generated through transactional fees on pharmaceutical and consumable distribution, plus recurring revenue from professional pharmacy and clinic operations under the SPS+ brand. Go-to-market is sales-led with field sales teams targeting healthcare providers, complemented by tendering participation, industry events, and the e-commerce storefront. The firmographic record lists 88 employees, although the operational scale implied by provincial-wide multi-channel distribution suggests the headcount figure refers to a subset of the workforce. Pricing is not publicly disclosed, consistent with a sector where government centralized procurement and hospital tendering set transaction terms. The company has won the 2023 Zhaopin China Best Employer Award (Guangzhou Best Employer), reflecting investment in employer brand and structured talent development programs (啟航計劃/續航計畫/遠航計畫 for early-career, plus five management-level programs).

Name

国药控股广州有限公司

Legal name

国药控股广州有限公司

Website

https://sinopharm-gz.com

Company type

Private

Operating status

Operating

Headcount range

51–100 employees

Short description

Sinopharm Holding Guangzhou Co., Ltd. is a Guangdong Province-based subsidiary of Sinopharm Holding that distributes pharmaceuticals, medical devices, and consumables to hospitals and operates the SPS+ professional pharmacy chain, retail clinics, and the 511yao.com B2B procurement platform across South China.

Ownership category

akta.pro rank

Product category

Pharmaceutical Distribution

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (42421), Refrigerated Warehousing and Storage (493120)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)

akta.pro secondary industries

Pharmaceutical & Biopharma Cold Chain Logistics (2–8°C, CRT, GDP) (TLAIAIAA), Pharmaceutical & Life Sciences Cold Chain Storage (2–8°C / CRT) (TLALABAF), Pharmaceutical & Biologics Courier (Rx, Specialty Drugs) (TLAAAIAB)

Keywords

• Pharmaceutical distribution
• Medical device supply
• Pharmaceutical logistics
• Retail pharmacy services
• Healthcare procurement

Headquarters

HQ city

Guangzhou

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Supply Chain, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical Distribution (传统业务): Core pharmaceutical distribution business serving hospitals, clinics, and retail pharmacies across Guangdong Province, covering traditional pharmaceutical products and medical consumables.
2. Medical Devices and Consumables (器械耗材): Distribution of medical devices and consumables to hospitals and healthcare facilities.
3. Retail Direct Sales (零售直销): Direct retail sales of pharmaceutical and health products to end consumers.
4. Retail Treatment/Clinic (零售诊疗): SPS+ professional pharmacy and retail clinic operations serving individual patients.
5. Pharmaceutical Logistics (医药物流): Specialized pharmaceutical logistics and cold-chain distribution services.
6. Innovation Business (创新业务): New and innovative business models including digital transformation initiatives and new pharmaceutical services.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

Sinopharm Holdings Guangzhou distributes pharmaceuticals, medical devices and consumables to hospitals, clinics and other healthcare institutions across Guangdong Province, while operating the SPS+ Professional Pharmacy retail chain and providing temperature-controlled pharmaceutical logistics with cold chain capabilities. The company serves as the regional distribution arm of Sinopharm Holding (Shanghai: 601869, HK: 01099), supporting both institutional buyers and retail consumers through multiple integrated channels.

Product overview

国药控股广州有限公司 (Sinopharm Guanzhou Co., Ltd.) operates as a comprehensive pharmaceutical distribution and healthcare services provider within the Sinopharm Group. The company's product portfolio centers on pharmaceutical wholesale distribution, medical devices and consumables, and retail pharmacy operations through its SPS+ professional pharmacy chain. Additional offerings include pharmaceutical logistics with cold chain capabilities, direct retail sales, retail medical consultation services, innovative healthcare business models, and a B2B e-commerce platform (511yao.com). The business operates under an integrated 'one body with two wings' strategy, combining traditional pharmaceutical distribution with innovation-driven healthcare services.

Differentiator

Problem solved

Functional benefit

Brands

• SPS+国药控股专业药房: Specialized pharmacy brand operated by the company offering pharmaceutical retail and treatment services.

Products and services

• Traditional Pharmaceutical Distribution

Quantifiable outcome

• AI talent training program launched covering management vision enhancement, practical tool application, and technology frontier analysis for employees at all levels.
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Eleven partnerships are on record, tiered minor and core.

• 百度飞桨（广州）人工智能产业赋能中心 (Baidu PaddlePaddle Guangzhou AI Industry Empowerment Center)minorStrategic or Co-development Partner · 1 January 2025国控广州 organized field visits to Baidu PaddlePaddle (Guangzhou) AI Industry Empowerment Center as part of its AI talent development program, enabling employees to experience AI technology applications in industrial scenarios and accumulate practical knowledge for technology-business integration.
• 百济神州 (BeiGene)coreStrategic or Co-development Partner · 1 January 2025Jointly organized '协同—颠覆性价值创造' (Collaboration - Disruptive Value Creation) training on May 27, 2025, with approximately 40 core procurement and sales staff participating. BeiGene provided a specialized instructor to deliver training on collaborative thinking, tools, and methodology application, aiming to optimize purchase-sales coordination and strategic cooperation between the two companies.
• 暨南大学 (Jinan University)minorStrategic or Co-development Partner · 1 January 2025University-enterprise cooperation for talent cultivation and recruitment, part of 国控广州's school-enterprise cooperation initiative.
• 广州中医药大学 (Guangzhou University of Chinese Medicine)minorStrategic or Co-development Partner · 1 January 2025University-enterprise cooperation for talent cultivation and recruitment.
• 广东药科大学 (Guangdong Pharmaceutical University)minorStrategic or Co-development Partner · 1 January 2025University-enterprise cooperation for talent cultivation and recruitment.
• 南方医科大学 (Southern Medical University)minorStrategic or Co-development Partner · 1 January 2025University-enterprise cooperation for talent cultivation and recruitment.
• 广州医科大学 (Guangzhou Medical University)minorStrategic or Co-development Partner · 1 January 2025University-enterprise cooperation for talent cultivation and recruitment.
• 广东食品药品职业学院 (Guangdong Food and Drug Vocational College)minorStrategic or Co-development Partner · 1 January 2025On April 26, 2024, signed a school-enterprise cooperation agreement and held a产学研基地 (industry-academia-research base) unveiling ceremony. The partnership aims to cultivate applied and compound talents through co-development of talent chain, innovation chain, and industry chain.
• 南昌大学软件学院 (Nanchang University Software College)minorStrategic or Co-development Partner · 1 January 2025On December 23, 2024, signed a graduate employment base cooperation agreement. The partnership focuses on software engineering talent cultivation, IT talent recruitment, and industry-academia-research cooperation, with university representatives visiting SPS+ professional pharmacies.
• 北京理工大学化学与化工学院 (Beijing Institute of Technology School of Chemistry and Chemical Engineering)minorStrategic or Co-development Partner · 1 January 2025On February 19, 国控广州 and Beijing Institute of Technology School of Chemistry and Chemical Engineering held a university-enterprise cooperation exchange seminar to explore talent cultivation models and build closer cooperation relationships.
• 广州医科大学附属肿瘤医院 (Guangzhou Medical University Affiliated Tumor Hospital)coreStrategic or Co-development Partner · 1 January 2025On November 25, 2025, launched the Day Infusion Center project (日间输注中心项目) jointly, aiming to create a new model of safe, efficient, and humanized infusion services for cancer patients.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Regional players

• 柳州医药股份有限公司 (Liuzhou Pharmaceutical): Regional pharmaceutical distributor (SSE:603368) headquartered in Guangxi. Adjacent geography to Guangdong and overlapping distribution model serving hospitals and retail pharmacies in southern China.
• 鹭燕医药股份有限公司 (Luyan Pharmaceutical): Regional pharmaceutical distributor (SZSE:002788) headquartered in Fujian with distribution across southern and eastern China. Comparable as a regional wholesaler/retailer focused on hospital channel.
• 英特集团 (Int'l Drug Group / 浙江省英特集团): Regional pharmaceutical distributor (SZSE:000411) primarily serving Zhejiang and eastern China. Comparable as a regional wholesaler with retail pharmacy operations, providing a peer benchmark for regional platform economics outside of Guangdong.

Direct peers

• 重药控股股份有限公司 (Sinopharm Chongqing Pharmaceutical / 重药控股): Another regional pharmaceutical distribution subsidiary under the Sinopharm Group (SSE:000950), operating across Southwest China. Directly comparable as a peer regional platform within the same parent group with similar hospital distribution, retail pharmacy, and logistics model.
• 九州通医药集团股份有限公司 (Jointown Pharmaceutical Group): Privately-controlled top-3 pharmaceutical distributor (SSE:600998) with strong presence among private hospitals, retail chains, and small clinics in southern China. Competes aggressively on price and customer service, particularly for non-public medical institutions.
• 上海医药集团股份有限公司 (Shanghai Pharmaceuticals Holding): One of China's 'Big 3' pharmaceutical distributors (SSE:601607, HKEX:02607). Competes with Sinopharm Holding's regional subsidiaries for hospital tenders, distribution contracts, and retail pharmacy acquisitions across southern China. Operates an integrated distribution + manufacturing + retail model.
• 华润医药集团有限公司 (China Resources Pharmaceutical Group): Major state-affiliated pharmaceutical distribution and manufacturing group listed in Hong Kong (HKEX:03320). Head-to-head competitor with Sinopharm in hospital drug distribution and operates its own retail pharmacy chain across China.
• 中国医药健康产业股份有限公司 (China National Pharmaceutical Health Industry / China Meheco): State-owned pharmaceutical distribution and international trading group under Sinopharm Group (SSE:600056). Engaged in pharmaceutical distribution, manufacturing, and international trade; competes for institutional and hospital tenders in multiple regions.

Broad incumbents

• 国药控股股份有限公司 (Sinopharm Holding Co., Ltd.): Direct parent (SSE:601869, HKEX:01099) and China's largest pharmaceutical distributor; same core business of hospital distribution, retail pharmacy, and logistics across the country. Most directly comparable peer because the subject operates as a wholly-owned regional platform under this group.

Emerging players

• 嘉事堂药业股份有限公司 (Cachet Pharmaceutical): Beijing-based pharmaceutical distributor with growing medical device distribution business (SZSE:002462). Compares on the medical device and consumable distribution segment (器械耗材), where Sinopharm Guangzhou is also building share.

Market position

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/%E5%9B%BD%E8%8D%AF%E6%8E%A7%E8%82%A1%E5%B9%BF%E5%B7%9E%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 国药控股广州有限公司